Phase II Study of Oral Tegafur/Uracil and Leucovorin plus Bevacizumab as a First-Line Therapy for Elderly Patients with Advanced or Metastatic Colorectal Cancer.

MLA

Mizushima, Tsunekazu, et al. “Phase II Study of Oral Tegafur/Uracil and Leucovorin plus Bevacizumab as a First-Line Therapy for Elderly Patients with Advanced or Metastatic Colorectal Cancer.” Oncology, vol. 89, no. 3, Aug. 2015, pp. 152–58. EBSCOhost, https://doi.org/10.1159/000381718.

APA

Mizushima, T., Tamagawa, H., Matsuda, C., Murata, K., Fukunaga, M., Ota, H., Hasegawa, J., Tsujie, M., Fukuzaki, T., Hata, T., Takemasa, I., Ikeda, M., Yamamoto, H., Sekimoto, M., Nezu, R., Doki, Y., & Mori, M. (2015). Phase II Study of Oral Tegafur/Uracil and Leucovorin plus Bevacizumab as a First-Line Therapy for Elderly Patients with Advanced or Metastatic Colorectal Cancer. Oncology, 89(3), 152–158. https://doi.org/10.1159/000381718

Chicago

Mizushima, Tsunekazu, Hiroshi Tamagawa, Chu Matsuda, Kohei Murata, Mutsumi Fukunaga, Hirofumi Ota, Junichi Hasegawa, et al. 2015. “Phase II Study of Oral Tegafur/Uracil and Leucovorin plus Bevacizumab as a First-Line Therapy for Elderly Patients with Advanced or Metastatic Colorectal Cancer.” Oncology 89 (3): 152–58. doi:10.1159/000381718.